Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07213609 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 22 → 27 locations
    • Eligibility criteria expanded, about 18 words
  2. Trial sites expanded: 19 → 22 locationsv8
  3. Trial sites expanded: 13 → 19 locationsv7
  4. Trial sites expanded: 9 → 13 locationsv6
  5. Study sites: 8 to 9v5
Show 3 earlier versionsHide 3 earlier versions
  1. Study sites: 4 to 8v4
  2. Primary endpoints: 7 to 5
    • Study sites: 3 to 4
    • Eligibility criteria shortened, about 13 words
    • Secondary endpoints: 13 to 11
    v3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 3
    • Start date changed from estimate of Oct 10, 2025 to Oct 20, 2025
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Solid tumours are abnormal lumps of tissue that can occur in different parts of the body. The tumours involved in this study have specific genetic characteristics that can make them more aggressive and challenging to treat. The study will test whether GSK5460025 alone or in combination (potential combinations may be included in future amendments to the protocol) with other anti-cancer agents can decrease tumor size, is safe, well-tolerated, and how the drug is processed in the body over time.
Trial Details
NCT Number NCT07213609
Lead Sponsor GlaxoSmithKline
Conditions
(from sponsor)		 Neoplasms, Colorectal, Neoplasms
Related terms Colonic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Neoplasms, Rectal Neoplasms, Turcot syndrome
Enrollment 47 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov